English
简体中文
Total: £ 56.28
Published Date: 2024-11-25 | Pages: 92 | Tables: 215 | Pharma & Healthcare
A pentavalent vaccine is a five-in-one vaccine that protects against diphtheria, tetanus, and whooping cough, hepatitis B, and Haemophilus influenza type b with just one dosage. One of the most well-known and successful techniques of preventing paediatric diseases is vaccination. The Government of India has achieved tremendous progress in preventing and controlling vaccine-preventable diseases since implementing the Universal Immunization Programme (UIP) (VPDs). The introduction of a pentavalent vaccination will help to minimise the number of cases of pneumonia and meningitis caused by the germs Haemophilus influenzae type b (Hib).
The global market for Pentavalent Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Pentavalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pentavalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Pentavalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Pentavalent Vaccine include Serum Institute of India, Panacea Drugs Pvt. Ltd, Shantha Biotechnics, Biological E. Ltd., Novartis AG, Crucell and Bio Farma, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pentavalent Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Pentavalent Vaccine by region & country, by Type, and by Application.
The Pentavalent Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pentavalent Vaccine.
Market Segmentation
By Company
Serum Institute of India
Panacea Drugs Pvt. Ltd
Shantha Biotechnics
Biological E. Ltd.
Novartis AG
Crucell
Bio Farma
Segment by Type:
Lyophilized
Liquid
Segment by Application
Retail Pharmacy
Hospital Pharmacy
E-commerce
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pentavalent Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Pentavalent Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Pentavalent Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Pentavalent Vaccine Product Introduction
1.2 Global Pentavalent Vaccine Market Size Forecast
1.2.1 Global Pentavalent Vaccine Sales Value (2019-2030)
1.2.2 Global Pentavalent Vaccine Sales Volume (2019-2030)
1.2.3 Global Pentavalent Vaccine Sales Price (2019-2030)
1.3 Pentavalent Vaccine Market Trends & Drivers
1.3.1 Pentavalent Vaccine Industry Trends
1.3.2 Pentavalent Vaccine Market Drivers & Opportunity
1.3.3 Pentavalent Vaccine Market Challenges
1.3.4 Pentavalent Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pentavalent Vaccine Players Revenue Ranking (2023)
2.2 Global Pentavalent Vaccine Revenue by Company (2019-2024)
2.3 Global Pentavalent Vaccine Players Sales Volume Ranking (2023)
2.4 Global Pentavalent Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Pentavalent Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Pentavalent Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Pentavalent Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Pentavalent Vaccine
2.9 Pentavalent Vaccine Market Competitive Analysis
2.9.1 Pentavalent Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Pentavalent Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pentavalent Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Lyophilized
3.1.2 Liquid
3.2 Global Pentavalent Vaccine Sales Value by Type
3.2.1 Global Pentavalent Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pentavalent Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Pentavalent Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Pentavalent Vaccine Sales Volume by Type
3.3.1 Global Pentavalent Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Pentavalent Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Pentavalent Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Pentavalent Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Retail Pharmacy
4.1.2 Hospital Pharmacy
4.1.3 E-commerce
4.2 Global Pentavalent Vaccine Sales Value by Application
4.2.1 Global Pentavalent Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pentavalent Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Pentavalent Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Pentavalent Vaccine Sales Volume by Application
4.3.1 Global Pentavalent Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Pentavalent Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Pentavalent Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Pentavalent Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Pentavalent Vaccine Sales Value by Region
5.1.1 Global Pentavalent Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pentavalent Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Pentavalent Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Pentavalent Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Pentavalent Vaccine Sales Volume by Region
5.2.1 Global Pentavalent Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Pentavalent Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Pentavalent Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Pentavalent Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Pentavalent Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Pentavalent Vaccine Sales Value, 2019-2030
5.4.2 North America Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Pentavalent Vaccine Sales Value, 2019-2030
5.5.2 Europe Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Pentavalent Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Pentavalent Vaccine Sales Value, 2019-2030
5.7.2 South America Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Pentavalent Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pentavalent Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pentavalent Vaccine Sales Value
6.2.1 Key Countries/Regions Pentavalent Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Pentavalent Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Pentavalent Vaccine Sales Value, 2019-2030
6.3.2 United States Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pentavalent Vaccine Sales Value, 2019-2030
6.4.2 Europe Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pentavalent Vaccine Sales Value, 2019-2030
6.5.2 China Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pentavalent Vaccine Sales Value, 2019-2030
6.6.2 Japan Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pentavalent Vaccine Sales Value, 2019-2030
6.7.2 South Korea Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pentavalent Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pentavalent Vaccine Sales Value, 2019-2030
6.9.2 India Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pentavalent Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Serum Institute of India
7.1.1 Serum Institute of India Company Information
7.1.2 Serum Institute of India Introduction and Business Overview
7.1.3 Serum Institute of India Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Serum Institute of India Pentavalent Vaccine Product Offerings
7.1.5 Serum Institute of India Recent Development
7.2 Panacea Drugs Pvt. Ltd
7.2.1 Panacea Drugs Pvt. Ltd Company Information
7.2.2 Panacea Drugs Pvt. Ltd Introduction and Business Overview
7.2.3 Panacea Drugs Pvt. Ltd Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Panacea Drugs Pvt. Ltd Pentavalent Vaccine Product Offerings
7.2.5 Panacea Drugs Pvt. Ltd Recent Development
7.3 Shantha Biotechnics
7.3.1 Shantha Biotechnics Company Information
7.3.2 Shantha Biotechnics Introduction and Business Overview
7.3.3 Shantha Biotechnics Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Shantha Biotechnics Pentavalent Vaccine Product Offerings
7.3.5 Shantha Biotechnics Recent Development
7.4 Biological E. Ltd.
7.4.1 Biological E. Ltd. Company Information
7.4.2 Biological E. Ltd. Introduction and Business Overview
7.4.3 Biological E. Ltd. Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Biological E. Ltd. Pentavalent Vaccine Product Offerings
7.4.5 Biological E. Ltd. Recent Development
7.5 Novartis AG
7.5.1 Novartis AG Company Information
7.5.2 Novartis AG Introduction and Business Overview
7.5.3 Novartis AG Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Novartis AG Pentavalent Vaccine Product Offerings
7.5.5 Novartis AG Recent Development
7.6 Crucell
7.6.1 Crucell Company Information
7.6.2 Crucell Introduction and Business Overview
7.6.3 Crucell Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Crucell Pentavalent Vaccine Product Offerings
7.6.5 Crucell Recent Development
7.7 Bio Farma
7.7.1 Bio Farma Company Information
7.7.2 Bio Farma Introduction and Business Overview
7.7.3 Bio Farma Pentavalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Bio Farma Pentavalent Vaccine Product Offerings
7.7.5 Bio Farma Recent Development
8 Industry Chain Analysis
8.1 Pentavalent Vaccine Industrial Chain
8.2 Pentavalent Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pentavalent Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Pentavalent Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Pentavalent Vaccine Market Trends
Table 2. Pentavalent Vaccine Market Drivers & Opportunity
Table 3. Pentavalent Vaccine Market Challenges
Table 4. Pentavalent Vaccine Market Restraints
Table 5. Global Pentavalent Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Pentavalent Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Pentavalent Vaccine Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Pentavalent Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Pentavalent Vaccine Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Pentavalent Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Pentavalent Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Pentavalent Vaccine
Table 13. Global Pentavalent Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pentavalent Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Pentavalent Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Pentavalent Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Pentavalent Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Pentavalent Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Pentavalent Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Pentavalent Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Pentavalent Vaccine Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Pentavalent Vaccine Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Pentavalent Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Pentavalent Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Pentavalent Vaccine Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Pentavalent Vaccine Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Pentavalent Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Pentavalent Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Pentavalent Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Pentavalent Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Pentavalent Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Pentavalent Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Pentavalent Vaccine Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Pentavalent Vaccine Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Pentavalent Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Pentavalent Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Pentavalent Vaccine Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Pentavalent Vaccine Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Pentavalent Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Pentavalent Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Pentavalent Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Pentavalent Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Pentavalent Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Pentavalent Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Pentavalent Vaccine Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Pentavalent Vaccine Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Pentavalent Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Pentavalent Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Pentavalent Vaccine Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Pentavalent Vaccine Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Pentavalent Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Pentavalent Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Pentavalent Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Pentavalent Vaccine Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Pentavalent Vaccine Sales Volume, (2025-2030) & (K Units)
Table 57. Serum Institute of India Company Information
Table 58. Serum Institute of India Introduction and Business Overview
Table 59. Serum Institute of India Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Serum Institute of India Pentavalent Vaccine Product Offerings
Table 61. Serum Institute of India Recent Development
Table 62. Panacea Drugs Pvt. Ltd Company Information
Table 63. Panacea Drugs Pvt. Ltd Introduction and Business Overview
Table 64. Panacea Drugs Pvt. Ltd Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Panacea Drugs Pvt. Ltd Pentavalent Vaccine Product Offerings
Table 66. Panacea Drugs Pvt. Ltd Recent Development
Table 67. Shantha Biotechnics Company Information
Table 68. Shantha Biotechnics Introduction and Business Overview
Table 69. Shantha Biotechnics Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Shantha Biotechnics Pentavalent Vaccine Product Offerings
Table 71. Shantha Biotechnics Recent Development
Table 72. Biological E. Ltd. Company Information
Table 73. Biological E. Ltd. Introduction and Business Overview
Table 74. Biological E. Ltd. Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Biological E. Ltd. Pentavalent Vaccine Product Offerings
Table 76. Biological E. Ltd. Recent Development
Table 77. Novartis AG Company Information
Table 78. Novartis AG Introduction and Business Overview
Table 79. Novartis AG Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Novartis AG Pentavalent Vaccine Product Offerings
Table 81. Novartis AG Recent Development
Table 82. Crucell Company Information
Table 83. Crucell Introduction and Business Overview
Table 84. Crucell Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Crucell Pentavalent Vaccine Product Offerings
Table 86. Crucell Recent Development
Table 87. Bio Farma Company Information
Table 88. Bio Farma Introduction and Business Overview
Table 89. Bio Farma Pentavalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Bio Farma Pentavalent Vaccine Product Offerings
Table 91. Bio Farma Recent Development
Table 92. Key Raw Materials Lists
Table 93. Raw Materials Key Suppliers Lists
Table 94. Pentavalent Vaccine Downstream Customers
Table 95. Pentavalent Vaccine Distributors List
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Pentavalent Vaccine Product Picture
Figure 2. Global Pentavalent Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Pentavalent Vaccine Sales Volume (2019-2030) & (K Units)
Figure 5. Global Pentavalent Vaccine Sales Price (2019-2030) & (US$/Unit)
Figure 6. Pentavalent Vaccine Report Years Considered
Figure 7. Global Pentavalent Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Pentavalent Vaccine Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Pentavalent Vaccine Revenue in 2023
Figure 10. Pentavalent Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Lyophilized Picture
Figure 12. Liquid Picture
Figure 13. Global Pentavalent Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Pentavalent Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Pentavalent Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Pentavalent Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Pentavalent Vaccine Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Retail Pharmacy
Figure 19. Product Picture of Hospital Pharmacy
Figure 20. Product Picture of E-commerce
Figure 21. Global Pentavalent Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Pentavalent Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Pentavalent Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Pentavalent Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Pentavalent Vaccine Price by Application (2019-2030) & (US$/Unit)
Figure 26. North America Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Pentavalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Pentavalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Pentavalent Vaccine Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Pentavalent Vaccine Sales Volume (%), (2019-2030)
Figure 38. United States Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 44. China Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 46. China Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 56. India Pentavalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Pentavalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 58. India Pentavalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 59. Pentavalent Vaccine Industrial Chain
Figure 60. Pentavalent Vaccine Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
